Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients
Jordi Río(Universitat Autònoma de Barcelona), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Mar Tintoré(Vall d'Hebron Hospital Universitari), Manuel Comabella(Universitat Autònoma de Barcelona), Nieves Téllez(Vall d'Hebron Hospital Universitari), Carlos Nos(Universitat Autònoma de Barcelona), Raúl Pelayo(Vall d'Hebron Hospital Universitari), Ingrid Galán(Universitat Autònoma de Barcelona)
Cited by 327
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k